More information: Syeda Maheen Batool et al, Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas, Nature Communications (2024). DOI: 10.1038/s41467-024-51332-7 ...

1 Genoptix Medical Laboratory, Carlsbad, CA, USA. 2 Yale University School of Medicine, New Haven, CT, USA 3 Clinical Development Laboratory, Merck & Company, Office: RY50-1E-144, Maildrop RY 50 ...

Minimal specimen requirements make it suitable for a wide range of tumor types and practice settings. The assay builds on the company’s tissue-based CGP platform, previously known as NeoComprehensive ...

On September 15, 2023, a new research paper was published in Oncotarget, entitled, “Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma.” ...

Real-time live tissue sensitivity assay could be used as a personalized strategy for pancreatic cancer. ... "To overcome the major hurdles of the PDX-based assay, we developed real time LTSA ...

The implementation of cell-based assays can improve the process of drug discovery and development by providing important biological information about drug action mechanisms, off-target effects ...

Actionability of comprehensive genomic profiling compared to the tissue-based and plasma-based assay in patients with metastatic breast cancer: A real-world study. Authors: Hiroshi Tada, Jun Yasuda, ...

The in vitro assays are based upon metabolic effects such as glucose uptake and oxidation of glucose to carbon dioxide by isolated surviving ... particularly with the rat-adipose-tissue assay, ...

The Cell-Based Assays Market is projected to grow from $35.3 billion in 2024 to $56.3 billion by 2029, at a 9.8% CAGR, driven by demand for drug discovery, ADME/toxicity testing, and precision ...

Ultrasensitive ctDNA assay could detect post-surgery colorectal cancer recurrence well before imaging-based detection of clinical relapse, according to results presented by Emma Titmuss, MSc, at ...